Atlas Trials

Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Clinical trial NCT04870190 · UNKNOWN

Trial details

NCT number
NCT04870190
Sponsor
Shanghai Chest Hospital
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
NSCLC
Start date
2021-06-01
Primary completion
2024-06-01
Enrollment
232

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.